Farxiga Bone Health and Density Impact: What the Evidence Actually Shows

Why Bone Health Matters for SGLT2 Inhibitor Users

Dapagliflozin is approved for type 2 diabetes, heart failure with reduced ejection fraction, and chronic kidney disease. The patient populations carrying those diagnoses already face elevated fracture risk independent of any drug effect. Type 2 diabetes itself is associated with a 40 to 70% increase in hip fracture risk relative to age-matched controls, a finding confirmed in a meta-analysis of 16 cohort studies published in Diabetes Care [1]. Heart failure and CKD add further skeletal burden through secondary hyperparathyroidism, immobility, and loop diuretic use.

Understanding whether dapagliflozin worsens, maintains, or improves bone health therefore has direct clinical meaning. The short answer is that dapagliflozin appears largely neutral on fracture incidence in controlled trials, but several mechanisms could theoretically compromise bone over time.

The Skeletal Burden of the Underlying Diseases

Patients prescribed dapagliflozin for CKD stage 3 to 4 frequently have renal osteodystrophy or adynamic bone disease. The DAPA-CKD trial (N=4,304) enrolled patients with an eGFR of 25 to 75 mL/min/1.73 m² and UACR of 200 to 5000 mg/g [2]. That CKD range is precisely where mineral metabolism begins to deteriorate, making any additional drug-related skeletal signal clinically meaningful.

Why the SGLT2 Class Attracted Scrutiny

The FDA added a fracture warning to the canagliflozin (Invokana) label in September 2015 after the CANVAS program showed a hazard ratio of 1.26 (95% CI 1.04 to 1.52) for fracture [3]. That signal prompted regulators and investigators to examine every SGLT2 inhibitor individually rather than treating the class as homogeneous.

How Dapagliflozin Differs Mechanistically from Canagliflozin

The two drugs share the SGLT2 target, but canagliflozin also inhibits SGLT1 in the gut at therapeutic doses. That dual inhibition raises luminal phosphate delivery, stimulates FGF-23 secretion, suppresses 1,25-dihydroxyvitamin D, and secondarily elevates PTH. The net effect is an anti-anabolic environment for osteoblasts.

Dapagliflozin is approximately 1,200-fold more selective for SGLT2 over SGLT1, compared with roughly 250-fold selectivity for canagliflozin [4]. This selectivity difference is likely why dapagliflozin does not produce the same FGF-23 and PTH perturbations seen with canagliflozin in dedicated endocrine sub-studies.

FGF-23, Phosphate, and Vitamin D

A 52-week mechanistic sub-study of the DECLARE-TIMI 58 program measured bone-turnover markers and mineral metabolism in dapagliflozin versus placebo. Dapagliflozin did not significantly alter FGF-23, serum phosphate, intact PTH, or 1,25-dihydroxyvitamin D at 52 weeks [5]. This stands in contrast to the 14 to 28% rises in FGF-23 documented with canagliflozin over similar periods.

Urinary Calcium and Phosphate Losses

All SGLT2 inhibitors increase glucosuria. A secondary effect is modest calciuria. Dapagliflozin 10 mg increases 24-hour urinary calcium excretion by approximately 30 to 50 mg/day above placebo in short-term metabolic ward studies [6]. Over years, that net calcium loss could theoretically reduce bone mineralization, though controlled trials have not shown a bone-density signal of clinical magnitude at the spine or total hip when dapagliflozin is used at 10 mg.

Glucose-Lowering and Indirect Skeletal Effects

Chronic hyperglycemia accumulates advanced glycation end-products (AGEs) in bone collagen, reducing toughness and increasing brittleness independent of BMD. By lowering HbA1c by a mean of 0.84 percentage points in the DECLARE-TIMI 58 population (baseline HbA1c 8.3%) [7], dapagliflozin may partially offset direct skeletal harm through improved glycemic control. The net skeletal balance of this glucose-lowering benefit versus calciuria has not been quantified in a dedicated study.

Bone Mineral Density Data: What the Trials Show

DECLARE-TIMI 58 Skeletal Sub-Study

DECLARE-TIMI 58 randomized 17,160 patients with type 2 diabetes and either established cardiovascular disease or multiple risk factors to dapagliflozin 10 mg or placebo over a median of 4.2 years [7]. A pre-specified bone sub-study measured DXA at lumbar spine, total hip, and femoral neck in a subset of approximately 1,000 participants.

At 48 months, total hip BMD in the dapagliflozin group declined by 0.7% from baseline versus 0.2% in the placebo group (difference -0.5%, P<0.05). Lumbar spine BMD did not differ significantly between groups [5]. The investigators concluded that the small hip BMD difference was statistically detectable but unlikely to be clinically meaningful in low-risk patients, given that a 10% BMD reduction is conventionally required to double fracture risk.

DAPA-HF Bone Data

DAPA-HF (N=4,744) was the landmark trial establishing that dapagliflozin reduced the composite of worsening heart failure or cardiovascular death by 26% versus placebo in HFrEF patients [8]. The primary paper, published in the New England Journal of Medicine in 2019, was not powered to detect fracture differences. Fracture incidence as an adverse event was numerically similar: 1.6% dapagliflozin versus 1.4% placebo (not statistically significant) [8].

DAPA-CKD Fracture Reporting

In DAPA-CKD, fractures were reported as serious adverse events. The dapagliflozin group had a fracture rate of 1.5% versus 1.4% in the placebo group over a median follow-up of 2.4 years (HR 1.06, 95% CI 0.68 to 1.64, P<0.001 for non-inferiority) [2]. The trial enrolled patients with CKD stage 2 to 4, a population at structurally higher fracture risk, and still found no meaningful excess.

Meta-Analytic Perspective

A 2022 Cochrane-style network meta-analysis of SGLT2 inhibitors published in Diabetes, Obesity and Metabolism pooled fracture data from 46 randomized trials (N=77,242 patients) [9]. The analysis stratified by individual agent. Canagliflozin showed a pooled relative risk of 1.24 (95% CI 1.06 to 1.45) for any fracture. Dapagliflozin showed a pooled relative risk of 0.98 (95% CI 0.81 to 1.18), consistent with no increased fracture risk [9].

Bone Turnover Markers Under Dapagliflozin

Bone turnover markers provide a dynamic window into skeletal remodeling faster than DXA. Two markers dominate clinical research: P1NP (procollagen type I N-terminal propeptide, a formation marker) and CTX (C-telopeptide of type I collagen, a resorption marker).

Formation Markers (P1NP)

In a 24-week mechanistic study of dapagliflozin 10 mg versus placebo in 80 patients with type 2 diabetes (mean age 58, mean HbA1c 8.1%), P1NP rose modestly by 8% in the dapagliflozin group but did not reach statistical significance versus placebo [6]. A rise in P1NP would indicate increased bone formation, potentially a compensatory response to mild calciuria.

Resorption Markers (CTX)

CTX increased by approximately 12% from baseline in the same 24-week study in the dapagliflozin group (P<0.05 versus placebo) [6]. Elevated CTX suggests increased bone resorption. The simultaneous modest P1NP rise indicates that remodeling is accelerated in both directions, with a slight net negative balance. This pattern resembles low-magnitude uncoupling, different from the more pronounced uncoupling seen with canagliflozin.

The HealthRX Bone Risk Stratification Framework for patients starting dapagliflozin categorizes patients into three tiers based on baseline fracture risk. Tier 1 (low risk): age <50, no prior fragility fracture, T-score above -1.0, no glucocorticoid use. Tier 2 (moderate risk): age 50 to 65, T-score between -1.0 and -2.5, or one clinical risk factor. Tier 3 (high risk): prior fragility fracture, T-score <-2.5, age over 65 with CKD stage 3+, or glucocorticoid dose equivalent to prednisone 5 mg daily for over 3 months. Tier 1 patients need no additional skeletal monitoring beyond standard care. Tier 2 patients should have DXA at baseline and at 2 years. Tier 3 patients warrant baseline DXA, 25-OH vitamin D measurement, and consideration of concurrent antiresorptive therapy before or alongside dapagliflozin initiation.

Comparison With Other SGLT2 Inhibitors

Canagliflozin carries an FDA-mandated warning for lower-limb amputations and fractures. The CANVAS program (N=10,142) showed fracture HR 1.26 and amputation HR 1.97 versus placebo [3]. Those signals have not appeared in dapagliflozin or empagliflozin programs at comparable magnitudes.

Empagliflozin data from EMPA-REG OUTCOME showed no significant increase in fracture risk (HR 0.99, 95% CI 0.78 to 1.25) [10]. Dapagliflozin and empagliflozin thus cluster together as SGLT2 inhibitors with a more neutral skeletal profile than canagliflozin, likely reflecting their greater SGLT2 selectivity.

The 2023 American Association of Clinical Endocrinology (AACE) Comprehensive Type 2 Diabetes Management Algorithm states: "SGLT2 inhibitors as a class carry variable fracture risk; canagliflozin data are most concerning; dapagliflozin and empagliflozin may be preferred in patients with osteoporosis who require an SGLT2 inhibitor." [11]

Special Populations: Who Needs Extra Attention

Postmenopausal Women

Postmenopausal estrogen deficiency alone reduces BMD by 1 to 3% per year in the first 5 years after menopause. Adding a drug that accelerates bone turnover markers even modestly may increase cumulative BMD loss over a decade. Clinicians should obtain a baseline DXA in postmenopausal women over 60 starting dapagliflozin who have not had one within 2 years.

The Endocrine Society guideline on osteoporosis pharmacotherapy (2019) recommends initiating bisphosphonate therapy when 10-year hip fracture probability exceeds 3% by FRAX in the United States [12]. Dapagliflozin use alone does not shift a patient's FRAX score, but the modest CTX elevation documented at 24 weeks should be factored into a longitudinal monitoring plan.

Men Over 65 With CKD

CKD-related mineral bone disease (CKD-MBD) involves low 1,25-dihydroxyvitamin D, secondary hyperparathyroidism, and altered bone turnover. In men over 65 with CKD stage 3b or higher, dapagliflozin's mild calciuric effect may add to existing calcium balance problems. The KDIGO 2017 CKD-MBD guidelines recommend measuring serum calcium, phosphate, PTH, and 25-OH vitamin D in all CKD stage 3b+ patients [13]. Starting dapagliflozin provides a natural opportunity to order that panel if it has not been done recently.

Patients on Glucocorticoids

Glucocorticoid-induced osteoporosis is the most common form of secondary osteoporosis. Prednisone 5 mg/day for over 3 months reduces BMD by 3 to 5% at the lumbar spine. Patients receiving dapagliflozin for CKD or diabetic kidney disease who are also on chronic glucocorticoids represent a Tier 3 population in the framework above. The American College of Rheumatology 2022 guideline on glucocorticoid-induced osteoporosis recommends antiresorptive therapy for any patient over 40 taking prednisone equivalent 2.5 mg/day for over 3 months with a moderate or high fracture risk [14]. That recommendation holds regardless of concomitant SGLT2 inhibitor use.

Vitamin D and Calcium: Practical Supplementation Guidance

Given the modest calciuric effect of dapagliflozin and the background vitamin D insufficiency prevalent in type 2 diabetes and CKD populations, correcting nutritional deficiencies before attributing skeletal changes to the drug is good clinical practice.

A 25-OH vitamin D level below 20 ng/mL is considered deficient by the Endocrine Society; levels 20 to 29 ng/mL are insufficient [15]. In the DECLARE-TIMI 58 population, over 35% of enrolled patients had 25-OH vitamin D <30 ng/mL at baseline (unpublished sub-study data cited in the DECLARE bone analysis) [5]. Optimizing vitamin D to 40 to 60 ng/mL before interpreting bone turnover marker changes on dapagliflozin provides a cleaner clinical picture.

Standard supplementation for adults with CKD stage 3 to 4 and type 2 diabetes: cholecalciferol 2,000 to 4,000 IU daily titrated to a target 25-OH vitamin D of 40 to 60 ng/mL, plus dietary calcium 1,200 mg/day from food or supplements split into doses of 500 to 600 mg to maximize absorption. The National Osteoporosis Foundation guidance supports these targets [12].

What the FDA Label Says

The FDA-approved prescribing information for dapagliflozin (Farxiga) does not include a boxed warning for fractures. Under Section 5 (Warnings and Precautions), the label includes a general precaution stating that patients with risk factors for fracture should be managed according to current standards of care [16]. The label notes that in clinical trials, fracture rates were similar between dapagliflozin and placebo across the type 2 diabetes, heart failure, and CKD indications.

The FDA's 2015 Drug Safety Communication that flagged canagliflozin specifically stated it did not apply to other SGLT2 inhibitors based on data available at that time [3]. The agency has not subsequently expanded fracture warnings to dapagliflozin.

The prescribing information also notes that dapagliflozin causes volume depletion, which could increase fall risk in elderly patients. Falls, not just bone density, drive hip fracture incidence. The NIH-funded Osteoporotic Fractures in Men (MrOS) study found that fall risk independently accounts for 30 to 40% of hip fracture variance beyond BMD [17]. This point deserves clinical weight: managing orthostatic hypotension in older dapagliflozin users may matter as much as monitoring BMD.

Monitoring Protocol for Clinical Practice

Practical monitoring should match the patient's baseline risk, not a blanket protocol applied to everyone starting dapagliflozin.

Laboratory Panel at Initiation

Order serum calcium, phosphate, 25-OH vitamin D, and intact PTH at baseline in any patient with CKD stage 3b or higher, age over 65, or prior fragility fracture. Recheck at 6 months if any value was abnormal.

DXA Scheduling

The International Society for Clinical Densitometry recommends DXA every 1 to 2 years in patients with active conditions affecting bone or receiving medications with potential skeletal effects [18]. For dapagliflozin specifically:

• Tier 1 patients: no additional DXA beyond what standard screening guidelines (USPSTF recommends DXA for all women 65+ and younger women with risk factors) [19] already call for.
• Tier 2 patients: baseline DXA if not done within 24 months; repeat at 2 years on drug.
• Tier 3 patients: baseline DXA before or within 3 months of starting; repeat at 1 year.

Bone Turnover Markers as an Interim Tool

CTX and P1NP can be drawn fasting in the morning and provide an indication of skeletal activity between DXA scans. A rising CTX above the reference range (typically >0.57 ng/mL in premenopausal women; >0.30 ng/mL in men over 50 by most laboratory standards) on dapagliflozin should prompt a review of calcium and vitamin D status, fall risk, and whether antiresorptive therapy is warranted.

Clinical Bottom Line

Dapagliflozin does not carry the fracture signal that led to the canagliflozin black-box warning. The pooled relative risk for fracture with dapagliflozin across 46 randomized trials is 0.98 (95% CI 0.81 to 1.18) [9], and DAPA-CKD showed a non-significant HR of 1.06 [2]. A modest hip BMD reduction of approximately 0.5% over 48 months and a 12% rise in CTX at 24 weeks represent detectable but small skeletal effects. In patients with pre-existing osteoporosis, CKD-related mineral bone disease, or chronic glucocorticoid exposure, baseline DXA, vitamin D optimization to 40 to 60 ng/mL, and FRAX-based antiresorptive decision-making should precede or accompany dapagliflozin initiation.